PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33493277-7 2021 In conclusion, aspirin reverses the endothelial dysfunction and oxidative stress caused by sFlt-1 and thus reduces apoptosis of preeclamptic trophoblasts by inactivating NF-kappaB signaling pathway. Aspirin 15-22 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 170-179 33229758-0 2020 Aspirin-Triggered Lipoxin Protects Lipopolysaccharide-Induced Acute Kidney Injury via the TLR4/MyD88/NF-kappaB Pathway. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 101-110 32429142-0 2020 Anti-Inflammatory and Reactive Oxygen Species Suppression through Aspirin Pretreatment to Treat Hyperoxia-Induced Acute Lung Injury in NF-kappaB-Luciferase Inducible Transgenic Mice. Aspirin 66-73 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 135-144 32429142-6 2020 This research uses an in vivo imaging system (IVIS) to investigate the mechanisms of aspirin"s anti-inflammatory and antioxidant effects on hyperoxia-induced ALI in nuclear factor kappaB (NF-kappaB)-luciferase transgenic mice. Aspirin 85-92 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 188-197 32429142-8 2020 An NF-kappaB-dependent bioluminescent signal was used in transgenic mice carrying the luciferase genes to monitor the anti-inflammatory effects of aspirin. Aspirin 147-154 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 3-12 32429142-9 2020 These results demonstrated that pretreatment with aspirin reduced luciferase expression, indicating that aspirin reduces NF-kappaB activation. Aspirin 50-57 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 121-130 32429142-9 2020 These results demonstrated that pretreatment with aspirin reduced luciferase expression, indicating that aspirin reduces NF-kappaB activation. Aspirin 105-112 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 121-130 32429142-11 2020 In addition, we demonstrated that pretreatment with aspirin significantly reduced the protein levels of phosphorylated protein kinase B, NF-kappaB and tumor necrosis factor alpha in NF-kappaB-luciferase+/+ transgenic mice. Aspirin 52-59 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 137-146 32429142-11 2020 In addition, we demonstrated that pretreatment with aspirin significantly reduced the protein levels of phosphorylated protein kinase B, NF-kappaB and tumor necrosis factor alpha in NF-kappaB-luciferase+/+ transgenic mice. Aspirin 52-59 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 182-191 32429142-12 2020 Thus, the effects of aspirin on the anti-inflammatory response and reactive oxygen species suppressive are hypothesized to occur through the NF-kappaB signaling pathway. Aspirin 21-28 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 141-150 30042442-6 2018 Furthermore, we found that Aspirin could block the activation of NF-kappaB signaling induced by PI3K inhibition, and combined use of GDC-0941 and Aspirin resulted in attenuated cell growth and enhanced apoptosis of 4T1 cells in the in vitro co-culture system with the presence of macrophages. Aspirin 27-34 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 65-74 31278071-6 2019 A mouse xenograft model, cell viability assay, colony formation assay, and immunohistochemistry analysis were used to evaluate the anti-fibrosis effect of aspirin through targeting the NF-kappaB/P4HA2 axis and LMCD1-AS1/let-7g/P4HA2 axis in vitro and in vivo. Aspirin 155-162 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 185-194 30633827-0 2019 Aspirin suppresses NFkappaB1 expression and inactivates cAMP signaling pathway to treat atherosclerosis. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 19-28 30633827-12 2019 It was proved that Aspirin increased cell apoptotic rate yet decreased cell proliferation rate of VSMCs to suppress AS progression by down-regulating the expression of NFkappaB1 and its targets, which might well provide us with more therapeutic strategies for treatment of AS. Aspirin 19-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 168-177 31938370-0 2018 Aspirin-triggered lipoxin A4 attenuates lipopolysaccharide-induced acute lung injury by inhibiting activation of mitogen-activated protein kinases and NF-kappaB in mice. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 151-160 29285098-0 2017 Aspirin suppresses TNF-alpha-induced MMP-9 expression via NF-kappaB and MAPK signaling pathways in RAW264.7 cells. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 58-67 29308184-12 2018 Additionally, the inhibitory effect from aspirin on the expression of TLR4 on C26 cells leads to the downregulation of NF-kappaB. Aspirin 41-48 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 119-128 29115440-0 2018 Aspirin ameliorates cerebral infarction through regulation of TLR4/NF-kappaB-mediated endoplasmic reticulum stress in mouse model. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 67-76 29115440-6 2018 Aspirin treatment suppressed toll-like receptor (TLR)4 and nuclear factor (NF)-kappaB expression in cerebrovascular endothelial cells. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 59-85 29115440-8 2018 It was identified that knockdown of TLR4 inhibited aspirin-mediated downregulation of NF-kappaB signaling pathway and ER stress in cerebrovascular endothelial cells. Aspirin 51-58 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 86-95 29115440-11 2018 These results suggested that aspirin may improve cerebral infarction by downregulating TLR4/NF-kappaB-mediated ER stress in a mouse model. Aspirin 29-36 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 92-101 24952332-0 2014 Acetylsalicylic acid enhances the anti-inflammatory effect of fluoxetine through inhibition of NF-kappaB, p38-MAPK and ERK1/2 activation in lipopolysaccharide-induced BV-2 microglia cells. Aspirin 0-20 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 95-104 28119929-6 2016 Proinflammatory cytokines were decreased and the expression of NF-kappaB p65 in acinar cell nuclei was suppressed after aspirin treatment. Aspirin 120-127 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 63-72 26093650-10 2015 RT-PCR demonstrated that the upregulation of NF-kappaB, MCP-1 and VCAM-1 after CA induction was reversed by aspirin treatment. Aspirin 108-115 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 45-54 29285098-6 2017 It was also observed that aspirin has a suppressive effect on the activation of nuclear factor (NF)-kappaB and inhibits the phosphorylation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases 1/2, p38 and c-Jun N-terminal kinase. Aspirin 26-33 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 80-106 29285098-7 2017 Furthermore, subsequent to inhibition of the MAPK pathway by specific inhibitors (PD98059, SB203580 and SP600125), the expression of MMP-9 was reduced, indicating that the inhibitory effect of aspirin on MMP-9 in TNF-alpha-treated RAW264.7 cells may be, at least in part, through suppression of NF-kappaB activation and the MAPK pathway. Aspirin 193-200 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 295-304 24952332-5 2014 Moreover, FLX could inhibit phosphorylation of nuclear factor-kappaB (NF-kappaB) and phosphorylation of p38 mitogen-activated protein kinase (MAPK), and the combined use with ASA could enhance these effects. Aspirin 175-178 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 47-68 18174252-7 2008 Compared with control, NO-ASA decreased NF-kappaB activation in intestinal epithelial cells of APC(min+/-) mice by 38.4% (P < 0.01). Aspirin 26-29 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 40-49 23553791-6 2013 Systemic administration of aspirin, which significantly reduces the levels of IFN-gamma and TNF-alpha, results in blockage of MSC deficiency and tumorigenesis by inhibition of NFkappaB/SMAD7 and NFkappaB/c-FOS and c-MYC pathways in OVX mice. Aspirin 27-34 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 176-184 23553791-6 2013 Systemic administration of aspirin, which significantly reduces the levels of IFN-gamma and TNF-alpha, results in blockage of MSC deficiency and tumorigenesis by inhibition of NFkappaB/SMAD7 and NFkappaB/c-FOS and c-MYC pathways in OVX mice. Aspirin 27-34 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 195-203 23536315-5 2013 The decrease in NET formation mediated by ASA, BAY-11-7082, and Ro 106-9920 was correlated with a significant reduction in the phosphorylation of NF-kappaB p65 subunit, indicating that the activation of this transcription factor is a relevant signaling pathway involved in the generation of DNA traps. Aspirin 42-45 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 146-155 23506847-5 2013 Herein, we demonstrate that aspirin-triggered LXA4 (15 mug/kg) s.c., twice a day, reduced NF-kappaB activation and levels of proinflammatory cytokines and chemokines, as well as increased levels of anti-inflammatory IL-10 and transforming growth factor-beta. Aspirin 28-35 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 90-99 12451498-7 2002 The fact that aspirin but not H7 blocks the enhancing effect suggests that NF-kappaB might be involved in wogonin-enhanced TNF-alpha gene expression. Aspirin 14-21 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 75-84 16887052-6 2006 Compared with ALI group, the level of NF-KappaB activity and the expression of ICAM-1 and P-selectin were obviously down regulated, and also the pathological lesion and inflammatory response of lung were improved in LMWH and ASA groups. Aspirin 225-228 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 38-47 16887052-13 2006 ASA plays the role as an inhibitor of NF-KappaB activation. Aspirin 0-3 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 38-47 16183169-5 2005 Aspirin, which has been shown to block phosphorylation of the IkappaB component of the cytoplasmic NF-kappaB complex, significantly suppressed glutamate-induced cell death, whereas the NF-kappaB decoy oligonucleotide potentiated it. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 99-108 16183169-5 2005 Aspirin, which has been shown to block phosphorylation of the IkappaB component of the cytoplasmic NF-kappaB complex, significantly suppressed glutamate-induced cell death, whereas the NF-kappaB decoy oligonucleotide potentiated it. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 185-194 16516312-5 2006 We confirmed the repressive effect of aspirin on GFAP transcription by GFAP promoter-driven reporter assay and found that one NF-kappaB binding site conserved in the mouse and human GFAP gene promoters is critical for this effect. Aspirin 38-45 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 126-135 34483913-0 2021 Aspirin Attenuates Cardiac Allograft Rejection by Inhibiting the Maturation of Dendritic Cells via the NF-kappaB Signaling Pathway. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 103-112 11855867-4 2002 Focus formation of PDGF-B-chain-transformed mouse fibroblasts was suppressed by treatment with acetylsalicylic acid (ASA) and salicylic acid, which are known inhibitors of NF-kappaB activation, but other nonsteroidal anti-inflammatory drugs that do not have an effect on NF-kappaB activity did not affect focus formation in these cells. Aspirin 95-115 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 172-181 11855867-4 2002 Focus formation of PDGF-B-chain-transformed mouse fibroblasts was suppressed by treatment with acetylsalicylic acid (ASA) and salicylic acid, which are known inhibitors of NF-kappaB activation, but other nonsteroidal anti-inflammatory drugs that do not have an effect on NF-kappaB activity did not affect focus formation in these cells. Aspirin 95-115 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 271-280 11855867-4 2002 Focus formation of PDGF-B-chain-transformed mouse fibroblasts was suppressed by treatment with acetylsalicylic acid (ASA) and salicylic acid, which are known inhibitors of NF-kappaB activation, but other nonsteroidal anti-inflammatory drugs that do not have an effect on NF-kappaB activity did not affect focus formation in these cells. Aspirin 117-120 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 172-181 11855867-4 2002 Focus formation of PDGF-B-chain-transformed mouse fibroblasts was suppressed by treatment with acetylsalicylic acid (ASA) and salicylic acid, which are known inhibitors of NF-kappaB activation, but other nonsteroidal anti-inflammatory drugs that do not have an effect on NF-kappaB activity did not affect focus formation in these cells. Aspirin 117-120 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 271-280 11855867-6 2002 Therefore, the transcription factor NF-kappaB plays a vital role in PDGF-B chain transformation of mouse fibroblast cells, and the NF-kappaB activity is sensitive to treatment with ASA. Aspirin 181-184 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 36-45 11855867-6 2002 Therefore, the transcription factor NF-kappaB plays a vital role in PDGF-B chain transformation of mouse fibroblast cells, and the NF-kappaB activity is sensitive to treatment with ASA. Aspirin 181-184 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 131-140 10419767-0 1999 Sites of action for future therapy: an adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice. Aspirin 78-85 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 148-156 10339595-2 1999 These include aspirin"s inhibition of NFkappaB translocation to the nucleus as well as the capacity of salicylates to uncouple oxidative phosphorylation (i.e., deplete ATP). Aspirin 14-21 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 38-46 9751197-10 1998 ), which, like aspirin and salicylate, has been reported to inhibit the transcription factor NF-kappaB, was also ineffective. Aspirin 15-22 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 93-102 34483913-13 2021 In vitro, aspirin decreased the activation of NF-kappaB signaling of DCs, as well as impeded MHCII and co-stimulatory molecules (CD80, CD86, and CD40) expression on DCs. Aspirin 10-17 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 46-55 34483913-15 2021 Conclusion: Aspirin inhibits the maturation of DCs through the NF-kappaB signaling pathway and attenuates acute cardiac allograft rejection. Aspirin 12-19 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 63-72 34208905-0 2021 Simultaneous Pretreatment of Aspirin and Omega-3 Fatty Acid Attenuates Nuclear Factor-kappaB Activation in a Murine Model with Ventilator-Induced Lung Injury. Aspirin 29-36 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 71-92 34208905-4 2021 We compared the lung inflammation after the sequential administration of lipopolysaccharides and mechanical ventilation between the pretreated simultaneous enteral aspirin and omega-3 fatty acid group and the non-pretreatment group, by quantifying NF-kappaB activation using an in vivo imaging system to detect bioluminescence signals. Aspirin 164-171 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 248-257 33743316-8 2021 We further demonstrated that aspirin inhibited the activation of NF-kappaB signaling and the release of its downstream pro-inflammatory cytokines. Aspirin 29-36 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 65-74 35111059-0 2021 Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-kappaB Signaling Pathway. Aspirin 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 126-135 35111059-11 2021 However, in vivo imaging revealed that posttreatment with aspirin reduced luciferase expression, suggesting that aspirin might reduce NF-kappaB activation. Aspirin 58-65 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 134-143 35111059-11 2021 However, in vivo imaging revealed that posttreatment with aspirin reduced luciferase expression, suggesting that aspirin might reduce NF-kappaB activation. Aspirin 113-120 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 134-143